Dan Peer

Tel Aviv University — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

62h-index23.8kcitations221works17.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(105), Advanced biosensing and bioanalysis techniques(66), Nanoparticle-Based Drug Delivery(44), Immunotherapy and Immune Responses(29), MicroRNA in disease regulation(22)

Publications214 total

The impact of chemical reactivity on the quality and stability of RNA–LNP pharmaceuticals  
Nature Reviews Chemistry·2025· 4 cited
Nanotechnology strategies for endometrium health: Are we on the right track?
Bioactive Materials·2025· 3 citedOpen Access
On The Retrograde Transport of RNA-Loaded Lipid Nanoparticles Designed for Brain Delivery
ACS Nanoscience Au·2025· 1 citedOpen Access
Targeting intestinal inflammation using locked nucleic acids delivered via lipid nanoparticles
Nature Communications·2025· 3 citedOpen Access
Challenges and opportunities in mRNA vaccine development against bacteria
Nature Microbiology·2025· 6 citedOpen Access
Publisher Correction: On the issue of transparency and reproducibility in nanomedicine
UNC Libraries·2025Open Access
Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague (Adv. Sci. 26/2025)
Advanced Science·2025Open Access
Effective communication with JCR editors in the peer review process
Journal of Controlled Release·2025Open Access
On‐Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles
Small·2025· 3 citedOpen Access
Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague
Advanced Science·2025· 4 citedOpen Access
Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle-Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors
ACS Nano·2025· 39 citedOpen Access
Voices of Nanomedicine: Blueprint Guidelines for Collaboration in Addressing Global Unmet Medical Needs
ACS Nano·2025· 15 citedOpen Access
Delivery of genetic medicines for muscular dystrophies
Cell Reports Medicine·2025· 9 citedOpen Access
Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer
Advanced Science·2024· 18 citedOpen Access
Lipid Nanoparticles With Fine‐Tuned Composition Show Enhanced Colon Targeting as a Platform for mRNA Therapeutics
Advanced Science·2024· 16 citedOpen Access
Immunogenic amines on lipid nanoparticles
Nature Biomedical Engineering·2024· 8 cited
The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes
Journal of Controlled Release·2024· 8 cited
1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
Annals of Oncology·2024· 5 citedOpen Access
Editorial: RNA vaccines for prevalent and newly emerging diseases
Frontiers in Immunology·2024· 2 citedOpen Access
Comparative optimization of polysaccharide-based nanoformulations for cardiac RNAi therapy
Nature Communications·2024· 20 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Srinivas Ramishetti(11), Meir Goldsmith(10), Rimona Margalit(7), Daniel Rosenblum(7), Niels Dammes(7), Inbal Hazan‐Halevy(6), Ranit Kedmi(5), Judy Lieberman(5), Nuphar Veiga(4), S. Moein Moghimi(4), Edo Kon(4), Gonna Somu Naidu(4), Jeffrey M. Karp(3), Róbert Langer(3), Motomu Shimaoka(3), Shoshy Mizrahy(3), Uri Elia(3), Keren Cohen(3), Omid C. Farokhzad(2), Wei Tao(2)